So here’s the big question for Hal Barron as he departs GlaxoSmithKline: Did he accomplish his mission?
The mission, put simply, was to turn around GSK’s labs when he was hired as chief scientific officer four years ago. At the time, the British drug maker was struggling to develop new medicines, its pipeline not exactly flush.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
